{"product_id":"bcli-vrio-analysis","title":"Brainstorm Cell Therapeutics Inc. (BCLI): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Brainstorm Cell Therapeutics Inc. (BCLI) truly built to last, or is its success merely fleeting? This VRIO analysis cuts straight to the core, dissecting the firm's Value, Rarity, Inimitability, and Organization to uncover the true source of its competitive edge - or where critical weaknesses lie. Dive in now to see the distilled summary of whether Brainstorm Cell Therapeutics Inc. (BCLI) possesses sustainable advantage and what that means for its future dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainstorm Cell Therapeutics Inc. (BCLI) - VRIO Analysis: Proprietary NurOwn (MSC-NTF) Platform for ALS\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at a therapy platform, NurOwn, that’s sitting right on the edge of a massive potential breakthrough for Amyotrophic Lateral Sclerosis (ALS). The core question for Brainstorm Cell Therapeutics is whether the upcoming data can convert this potential into a durable competitive moat. Let’s break down the VRIO framework for this specific asset.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Offers a potential disease-modifying therapy for ALS, addressing a massive unmet medical need.\u003c\/h3\u003e\n\u003cp\u003eThe value proposition here is huge because ALS is a devastating disease with very few effective treatments. NurOwn, which uses autologous MSC-NTF cells (mesenchymal stem cells producing neurotrophic factors), aims to slow disease progression, not just manage symptoms. Honestly, any therapy that can meaningfully alter the course of ALS is inherently valuable. Consider the Expanded Access Program data: 100% of those treated survived beyond 5 years from symptom onset, with a median survival of 6.8 years. That level of potential impact screams high value.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: The specific cell therapy approach, producing neurotrophic factors, is distinct in the current ALS pipeline.\u003c\/h3\u003e\n\u003cp\u003eWhile other cell therapies exist, Brainstorm Cell Therapeutics’ specific approach - using the patient's own cells to produce a cocktail of neurotrophic factors - is quite unique in the late-stage ALS landscape right now. They secured Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for this reason. It’s not just a small molecule; it’s a complex, personalized biological product. This specificity makes it rare, but rarity alone doesn't guarantee advantage.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High barrier due to years of clinical data and the complexity of autologous cell production.\u003c\/h3\u003e\n\u003cp\u003eIt’s tough to copy this quickly. Imitation is hard because it requires replicating years of clinical experience, navigating the regulatory path (they have a Special Protocol Assessment, or SPA, with the FDA for the trial design), and mastering the autologous cell manufacturing process. Manufacturing autologous (from the patient's own body) cell therapies is a major operational hurdle, involving specialized facilities and strict controls. The complexity of the Chemistry, Manufacturing, and Controls (CMC) aspects is a significant barrier to entry for a competitor trying to jump in fast.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Management is laser-focused on initiating the Phase 3b ENDURANCE study to generate confirmatory data.\u003c\/h3\u003e\n\u003cp\u003eManagement’s focus is clearly on execution for the Phase 3b ENDURANCE study, which the FDA has cleared. The organization is structured around getting this trial running to generate the data needed for a Biologics License Application (BLA) submission. They have secured a Letter of Intent (LOI) with Minaris Advanced Therapies for manufacturing support, showing they are aligning resources for this critical next step. However, the organization's current financial footing presents a risk to sustained focus.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on their recent operational state as of Q3 2025:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003eValue (as of Sep 30, 2025)\u003c\/td\u003e\n    \u003ctd\u003eContext\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCash Position\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$0.23 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eLow liquidity requiring immediate funding action\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePhase 3b Trial Enrollment Target\u003c\/td\u003e\n    \u003ctd\u003eApprox. \u003cstrong\u003e200\u003c\/strong\u003e participants\u003c\/td\u003e\n    \u003ctd\u003eENDURANCE study size\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePrimary Endpoint Readout\u003c\/td\u003e\n    \u003ctd\u003eWeek \u003cstrong\u003e24\u003c\/strong\u003e (Part A)\u003c\/td\u003e\n    \u003ctd\u003eALSFRS-R change from baseline\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n    \u003ctd\u003eApprox. \u003cstrong\u003e$2.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eBurn rate against cash reserves\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQ3 2025 R\u0026amp;D Spend (Net)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$0.9 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eInvestment in the clinical program\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is the immediate need to secure non-dilutive funding or other capital to fully support the 24-week trial execution, which is a key organizational challenge right now.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary; sustained only if the Phase 3b trial is successful and leads to BLA approval.\u003c\/h3\u003e\n\u003cp\u003eRight now, the advantage is only \u003cstrong\u003etemporary\u003c\/strong\u003e. The current data is compelling, especially the long-term survival signals, but it is not yet a BLA-supporting, approved product. The entire competitive future hinges on the outcome of the Phase 3b ENDURANCE study, specifically the primary endpoint at Week 24. If the trial hits its mark, the advantage becomes sustained, backed by proprietary manufacturing and clinical experience. If it fails, the advantage evaporates, and the company faces significant headwinds. If onboarding takes 14+ days, churn risk rises.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSecure FDA acceptance of Part A data for BLA submission.\u003c\/li\u003e\n  \u003cli\u003eSuccessfully enroll all 200 planned participants.\u003c\/li\u003e\n  \u003cli\u003eDemonstrate statistically significant slowing of ALSFRS-R decline.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainstorm Cell Therapeutics Inc. (BCLI) - VRIO Analysis: Intellectual Property: Foundational Exosome Technology Patent\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis focuses on the U.S. Patent Application 16\/981,757, which received a Notice of Allowance from the USPTO on December 3, 2024, covering proprietary exosome technology.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Creates a second, proprietary platform for future drug delivery, diversifying the company’s long-term value.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Receiving a Notice of Allowance for a foundational patent in this emerging area is quite rare.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Strong legal protection makes direct imitation of the patented technology very difficult for competitors. The expected protection extends until \u003cstrong\u003eApril 10, 2039\u003c\/strong\u003e, subject to standard term adjustments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is actively using this development to strengthen its overall IP portfolio.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; as long as the patent remains valid, it provides a legal moat.\u003c\/p\u003e\n\n\u003cp\u003eThe exosome technology is derived from mesenchymal stem cells that secrete neurotrophic factors (MSC-NTF) and is produced in bioreactors.\u003c\/p\u003e\n\n\u003cul\u003e\n    \u003cli\u003eThe exosomes carry neurotrophic factors such as \u003cstrong\u003eLIF\u003c\/strong\u003e, \u003cstrong\u003eVEGFA\u003c\/strong\u003e, and \u003cstrong\u003eGDF-15\u003c\/strong\u003e, potentially including additional proteins or microRNA molecules.\u003c\/li\u003e\n    \u003cli\u003eThe company's broader intellectual property includes a European Patent Office granted patent No. \u003cstrong\u003e3105587\u003c\/strong\u003e and an Australian patent Office granted patent No. \u003cstrong\u003e2019252987\u003c\/strong\u003e for related exosome technology and methods.\u003c\/li\u003e\n    \u003cli\u003eThe company's market capitalization was noted as \u003cstrong\u003e$9.8M\u003c\/strong\u003e in the context of this patent announcement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eMetric\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003eData Point\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003eDate\/Context\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eUS Patent Application Number\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e16\/981,757\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eNotice of Allowance Received\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eExpected Patent Protection End Date\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003eApril 10, 2039\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eSubject to standard term adjustments\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCash, Cash Equivalents, Restricted Cash\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e$0.23 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eQuarterly Net Loss\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e$2.1 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eFor the quarter ended September 30, 2025\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eQuarterly R\u0026amp;D Expenditures, Net\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e$0.9 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eFor the quarter ended September 30, 2025\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe company is pursuing strategic collaborations for the exosome platform.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainstorm Cell Therapeutics Inc. (BCLI) - VRIO Analysis: Deep Clinical Data and Pharmacogenomic Insights\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The data, especially linking response to the UNC13A genotype, can de-risk future trials by identifying likely responders. This pharmacogenomic analysis was presented as Breakthrough Science at the ISCT 2025 Meeting in May 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Longitudinal data sets tied to specific genetic biomarkers in advanced neurodegeneration are scarce. Survival data from the Expanded Access Program (EAP) showed \u003cstrong\u003e90%\u003c\/strong\u003e of participants (9\/10) survived more than \u003cstrong\u003efive years\u003c\/strong\u003e from ALS symptom onset, compared to published estimates of approximately \u003cstrong\u003e10%\u003c\/strong\u003e survival.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The decade of collected data and published findings are not easily replicated by rivals. The NurOwn clinical program includes biomarker data collected at \u003cstrong\u003eseven longitudinal time points\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Insights were recently highlighted at the ISCT 2025 Meeting, showing active use of this knowledge. The company is advancing pre-initiation activities for the Phase 3b ENDURANCE study, which is expected to enroll approximately \u003cstrong\u003e200 participants\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this proprietary knowledge base is difficult for others to match quickly.\u003c\/p\u003e\n\u003cp\u003eSelected Financial and Clinical Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric Category\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eValue\/Period\u003c\/td\u003e\n\u003ctd\u003eReference Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trial Enrollment\u003c\/td\u003e\n\u003ctd\u003ePhase 3b ENDURANCE Expected Participants\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e200\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUpcoming\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurvival Data (EAP)\u003c\/td\u003e\n\u003ctd\u003eParticipants Surviving \u0026gt; 5 Years from Symptom Onset\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e90%\u003c\/strong\u003e (9\/10)\u003c\/td\u003e\n\u003ctd\u003eAs of June 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurvival Data (EAP)\u003c\/td\u003e\n\u003ctd\u003eMedian Survival from Symptom Onset\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.8 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancials (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$2.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQuarter Ended Sept 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancials (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eNet Loss Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.19\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter Ended Sept 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancials (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eResearch and Development Expenditures, net\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter Ended Sept 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancials (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Restricted Cash\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$0.23 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of Sept 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eHistorical Clinical Response Observation:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 2a Study: \u003cstrong\u003e92%\u003c\/strong\u003e of subjects with $\\ge \u003cstrong\u003e3$ months\u003c\/strong\u003e follow-up experienced an improvement in the rate of disease progression after NurOwn administration.\u003c\/li\u003e\n\u003cli\u003ePhase 2a Study: ALSFRS progression rate slowed by \u003cstrong\u003e45%\u003c\/strong\u003e (from 1.41 points\/month to 0.78 points\/month) for the \u003cstrong\u003ethree months\u003c\/strong\u003e following treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRecent Quarterly Financial Performance Comparison:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Net Loss: \u003cstrong\u003e$2.1 million\u003c\/strong\u003e vs. Q3 2024 Net Loss of \u003cstrong\u003e$2.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ2 2025 Net Loss: Approximately \u003cstrong\u003e$2.9 million\u003c\/strong\u003e vs. Q2 2024 Net Loss of approximately \u003cstrong\u003e$2.54 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Net Loss: Approximately \u003cstrong\u003e$2.9 million\u003c\/strong\u003e vs. Q1 2024 Net Loss of approximately \u003cstrong\u003e$3.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainstorm Cell Therapeutics Inc. (BCLI) - VRIO Analysis: Special Protocol Assessment (SPA) Regulatory Clarity\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The SPA agreement with the U.S. Food and Drug Administration (FDA) provides a clear, pre-agreed path for the confirmatory trial. The trial design, ENDURANCE (NCT06973629), is set to enroll approximately \u003cstrong\u003e200\u003c\/strong\u003e participants.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Securing the first-ever SPA for an ALS study is a unique regulatory achievement. The prior Phase 3 trial (NCT03280056) had a 33% responder rate for NurOwn treated patients versus 28% for placebo overall, but the SPA-cleared Phase 3b trial is designed to support a BLA submission based on specific endpoints agreed upon with the FDA.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific terms of the SPA agreement are unique to Brainstorm Cell Therapeutics Inc. and cannot be copied. The agreement validates the protocol, including the primary efficacy measure being the change from baseline to Week \u003cstrong\u003e24\u003c\/strong\u003e on the ALSFRS-R.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e FDA clearance for the Phase 3b trial is secured, allowing the company to move forward with operational readiness. The company reported a cash position of approximately \u003cstrong\u003e$0.23 million\u003c\/strong\u003e as of September 30, 2025, while advancing pre-initiation activities.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage fades once the BLA submission based on the trial is complete. Data from the NurOwn Expanded Access Program showed 100% of participants surviving beyond \u003cstrong\u003e5\u003c\/strong\u003e years from ALS symptom onset, with a median survival of \u003cstrong\u003e6.8\u003c\/strong\u003e years.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eSpecific Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Timeframe\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Design\u003c\/td\u003e\n\u003ctd\u003ePlanned Enrollment (Phase 3b ENDURANCE)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e200\u003c\/strong\u003e participants\u003c\/td\u003e\n\u003ctd\u003ePhase 3b Trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Design\u003c\/td\u003e\n\u003ctd\u003ePlacebo-Controlled Period (Part A)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e24\u003c\/strong\u003e weeks\u003c\/td\u003e\n\u003ctd\u003eSPA-agreed design\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEfficacy Endpoint\u003c\/td\u003e\n\u003ctd\u003ePrimary Measure Timepoint\u003c\/td\u003e\n\u003ctd\u003eWeek \u003cstrong\u003e24\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eChange on ALSFRS-R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistorical Data\u003c\/td\u003e\n\u003ctd\u003eExpanded Access Median Survival\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6.8\u003c\/strong\u003e years\u003c\/td\u003e\n\u003ctd\u003ePost-symptom onset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Data\u003c\/td\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.23 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe Phase 3b trial structure includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePart A:\u003c\/strong\u003e A \u003cstrong\u003e24\u003c\/strong\u003e-week randomized, double-blind, placebo-controlled period.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePart B:\u003c\/strong\u003e A subsequent \u003cstrong\u003e24\u003c\/strong\u003e-week open-label extension where all participants receive NurOwn.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePrior trial data points include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOverall NurOwn response rate in NCT03280056: \u003cstrong\u003e33%\u003c\/strong\u003e versus placebo at \u003cstrong\u003e28%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResponse rate for AC genotype subgroup in NCT03280056: \u003cstrong\u003e65%\u003c\/strong\u003e for NurOwn versus \u003cstrong\u003e29%\u003c\/strong\u003e for placebo (P=\u003cstrong\u003e0.011\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eFDA Advisory Committee vote against prior approval (Sept 2023): \u003cstrong\u003e17-1\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainstorm Cell Therapeutics Inc. (BCLI) - VRIO Analysis: Secured, Specialized Manufacturing Partnerships\n\u003c\/h2\u003e\n\u003cp\u003eThe operational risk associated with producing autologous cell therapy is mitigated through securing capacity with specialized Contract Development and Manufacturing Organizations (CDMOs).\u003c\/p\u003e\n\n\u003ch\u003eValue: Mitigates the massive operational risk of producing autologous cell therapy by securing capacity with experts.\u003c\/h\u003e\n\u003cp\u003eSecuring manufacturing capacity addresses the critical bottleneck in autologous cell therapy production, which is inherently complex and subject to high failure rates.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Access to specialized, global Contract Development and Manufacturing Organization (CDMO) capacity for cell and gene therapies is constrained.\u003c\/h\u003e\n\u003cp\u003eThe constraint on specialized capacity is a market reality for cell and gene therapies.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Phase 3b ENDURANCE study is expected to enroll approximately \u003cstrong\u003e200\u003c\/strong\u003e participants at leading ALS centers.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenditures, net, for the quarter ended June 30, 2025, were \u003cstrong\u003e$1.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eImitability: While CDMOs are available, the specific Letter of Intent (LOI) with Minaris Advanced Therapies and the Pluri partnership are exclusive arrangements.\u003c\/h\u003e\n\u003cp\u003eThe specific contractual nature of the agreements limits immediate replication by competitors.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner\u003c\/td\u003e\n\u003ctd\u003eAgreement Type\u003c\/td\u003e\n\u003ctd\u003eManufacturing Scope\u003c\/td\u003e\n\u003ctd\u003eStatus\/Location Detail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinaris Advanced Therapies\u003c\/td\u003e\n\u003ctd\u003eLetter of Intent (LOI)\u003c\/td\u003e\n\u003ctd\u003eNurOwn for upcoming Phase 3b clinical trial\u003c\/td\u003e\n\u003ctd\u003eTechnology transfer has started in New Jersey (per outline)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePluri Inc.\u003c\/td\u003e\n\u003ctd\u003eMemorandum of Understanding (MOU)\u003c\/td\u003e\n\u003ctd\u003eNurOwn for planned Phase 3b trial\u003c\/td\u003e\n\u003ctd\u003eGMP-compliant manufacturing at facilities in Israel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eOrganization: Technology transfer has started with Minaris in New Jersey for Phase 3b supply.\u003c\/h\u003e\n\u003cp\u003eOperational readiness is being established through active technology transfer processes.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe MOU with Pluri enables BrainStorm to begin transfer of its manufacturing technology upon finalizing the binding definitive agreement.\u003c\/li\u003e\n\u003cli\u003eThe Pluri collaboration aims to fulfill essential supply requirements of NurOwn® as BrainStorm advances its Phase 3b clinical trial.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and restricted cash were approximately \u003cstrong\u003e$0.23 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage: Temporary; dependent on the ongoing performance and terms of the specific partnership agreements.\u003c\/h\u003e\n\u003cp\u003eThe advantage is contingent on the successful execution and continuation of the agreements.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe MOU with Pluri was announced on November 11, 2024.\u003c\/li\u003e\n\u003cli\u003eThe Phase 3b trial Part A primary efficacy endpoint is change in ALSFRS-R from baseline to Week \u003cstrong\u003e24\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainstorm Cell Therapeutics Inc. (BCLI) - VRIO Analysis: Platform Versatility Beyond ALS Indication\n\u003c\/h2\u003e\n\u003cp\u003eThe platform's potential extends beyond Amyotrophic Lateral Sclerosis (ALS) into other neurodegenerative areas, specifically Multiple Sclerosis (MS), which influences the Total Addressable Market (TAM) assessment.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue: The potential to treat other neurodegenerative diseases, like Multiple Sclerosis (MS), broadens the total addressable market significantly.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe NurOwn® platform is being explored for indications including Parkinson's Disease and Alzheimer's Disease, in addition to MS. The completed Phase 2 trial in progressive MS demonstrates the platform's potential applicability across different neurological pathways.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity: Having positive Phase 2 data in MS alongside ALS development is a rare dual-track asset profile.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe completion of the Phase 2 trial in progressive MS, supported by a grant from the National MS Society, provides an established data set outside of the primary ALS indication. Key statistics from this trial include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrolled Participants (Phase 2 MS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eParticipants Receiving All 3 Treatments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMean Age at Screening\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e47 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMean EDSS Score at Screening\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.4\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResponders (≥25% improvement in T25FW or 9HPT)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatched CLIMB Registry Responders\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe platform is also advancing into an allogeneic exosome-based technology.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability: The results are unique, but the underlying platform technology could eventually be mimicked by well-funded competitors.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe proprietary cell culture methods used to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) are specific to the company's current manufacturing process. The company also received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization: The company continues to reference its completed Phase 2 trial in progressive MS.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe company has publicly referenced the completion of the Phase 2 open-label multicenter trial (NCT03799718) in progressive MS. The company reported a net loss of approximately \u003cstrong\u003e$11.6 million\u003c\/strong\u003e for the twelve months ended December 31, 2024, with cash, cash equivalents, and short-term bank deposits of approximately \u003cstrong\u003e$0.4 million\u003c\/strong\u003e as of that date.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage: Temporary; this advantage lasts until a competitor successfully launches a similar multi-indication platform.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe current advantage is derived from having completed clinical data in a second major indication (MS) using the core cell therapy platform, which supports the platform's potential for broader application across neurodegenerative diseases. The company employed \u003cstrong\u003e43\u003c\/strong\u003e full-time employees as of a recent report.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainstorm Cell Therapeutics Inc. (BCLI) - VRIO Analysis: Demonstrated Operational Cost Discipline\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eLower operating expenses extend the company’s cash runway, which is vital given the tight finances. Cash, cash equivalents, and restricted cash were approximately $0.23 million as of September 30, 2025.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eWhile cost control is always sought, the reported year-over-year reduction in G\u0026amp;A expenses shows focused execution.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThe discipline is company-specific, though the processes themselves can be copied.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eGeneral and administrative expenses dropped from approximately $2.0 million in Q3 2024 to $1.1 million in Q3 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2024 Amount\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003eApproximately $2.0 million\u003c\/td\u003e\n\u003ctd\u003eApproximately $1.1 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenditures, Net\u003c\/td\u003e\n\u003ctd\u003eApproximately $1.0 million\u003c\/td\u003e\n\u003ctd\u003eApproximately $0.9 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003eApproximately $2.7 million\u003c\/td\u003e\n\u003ctd\u003eApproximately $2.1 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe operational cost discipline is further evidenced by the following quarterly financial metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGeneral and administrative expenses decreased by 45% year-over-year for Q3 2025 compared to Q3 2024 (from $2.0 million to $1.1 million).\u003c\/li\u003e\n\u003cli\u003eResearch and development expenditures, net, decreased from approximately $1.0 million in Q3 2024 to $0.9 million in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eNet loss narrowed from approximately $2.7 million in Q3 2024 to approximately $2.1 million in Q3 2025, partially driven by lower operating expenses.\u003c\/li\u003e\n\u003cli\u003eNet loss per share improved from $(0.51) in Q3 2024 to $(0.19) in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; this efficiency requires constant management vigilance to maintain.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainstorm Cell Therapeutics Inc. (BCLI) - VRIO Analysis: Mobilized ALS Community Advocacy Support\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below focuses exclusively on providing real-life statistical and financial data points relevant to the Mobilized ALS Community Advocacy Support component of the VRIO framework for BCLI.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue: The Citizen Petition filed with the FDA demonstrates deep, grassroots belief in NurOwn, creating external pressure for regulatory review.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe external pressure is quantified by the evidence cited in the community-led effort, which seeks approval based on the following Expanded Access Program (EAP) data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eNurOwn EAP Data\u003c\/th\u003e\n\u003cth\u003eNatural ALS History Benchmark\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e5-Year Survival Rate\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e (\u003cstrong\u003e10\/10\u003c\/strong\u003e participants)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e20%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Survival from Symptom Onset\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.8 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2-5 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRate of Progression (ALSFRS-R)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e85%\u003c\/strong\u003e slowing (from $\\ge 1$ pt\/month loss to \u003cstrong\u003e0.15pts\/month\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eLoss of $\\ge 1$ point per month\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime-to-Non-Invasive Ventilation (NIV)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e60-103 months\u003c\/strong\u003e (\u003cstrong\u003e4x-7x\u003c\/strong\u003e longer)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe underlying disease context underscores the value of this advocacy:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFatality rate associated with an ALS diagnosis: \u003cstrong\u003e100%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePatients living with ALS in the United States: Approximately \u003cstrong\u003e30,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: A formal, well-supported petition from the patient community requesting a specific regulatory action is uncommon.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe formal nature of the request is evidenced by the submission's scope and the FDA's subsequent action:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Citizen's Petition submitted to the FDA was a \u003cstrong\u003e309-page\u003c\/strong\u003e document.\u003c\/li\u003e\n\u003cli\u003eThe FDA announced it would review the Citizen Petition.\u003c\/li\u003e\n\u003cli\u003eThe petition was filed on July 3, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: This cannot be manufactured; it stems from genuine patient experience and advocacy mobilization.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe foundation of the support is the real-world clinical outcome data from patients who received the therapy, which is not replicable through standard corporate actions:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe petition is backed by a decade of real-world data from the NurOwn trials and the Expanded Access Program (EAP).\u003c\/li\u003e\n\u003cli\u003eThe EAP data showed \u003cstrong\u003e100%\u003c\/strong\u003e of participants survived more than 5 years.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: Management is actively acknowledging and engaging with the petition filed by ALS patient representatives.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eBCLI management's engagement is situated within its ongoing corporate and clinical development activities:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBCLI President and CEO, Chaim Lebovits, stated, 'We support the FDA's consideration of the Citizen Petition'.\u003c\/li\u003e\n\u003cli\u003eBCLI is proceeding with its planned Phase 3b ENDURANCE trial, which is designed to enroll approximately \u003cstrong\u003e200 participants\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2025, BCLI's cash, cash equivalents, and restricted cash were approximately \u003cstrong\u003e$0.23 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of June 30, 2025, BCLI's cash, cash equivalents, and restricted cash were approximately \u003cstrong\u003e$1.03 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Temporary; the impact is event-driven and relies on sustained community engagement.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe advantage is tied to the specific regulatory event and the community's continued mobilization, which is distinct from BCLI's internal R\u0026amp;D pipeline:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company's market value as of July 8, 2025, was reported at \u003cstrong\u003e$11.22 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eBCLI's Q3 2025 Research and development expenditures, net, were \u003cstrong\u003e$0.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainstorm Cell Therapeutics Inc. (BCLI) - VRIO Analysis: Patented Ex Vivo Cell Expansion Protocol\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003ePatented Ex Vivo Cell Expansion Protocol\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: This is the 'secret sauce' - the specific, patented conditions that force the mesenchymal stem cells to secrete high levels of therapeutic neurotrophic factors. The platform leverages mesenchymal stem cells (MSCs) engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.\u003c\/p\u003e\n\u003cp\u003eRarity: The precise, proprietary protocol for cell conversion is a key trade secret protected by IP. The NurOwn technology platform has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype.\u003c\/p\u003e\n\u003cp\u003eImitability: Difficult to copy without infringing on process patents or reverse-engineering the exact conditions. The protocol is the foundation upon which the entire NurOwn technology platform is built.\u003c\/p\u003e\n\u003cp\u003eOrganization: This protocol is the foundation upon which the entire NurOwn technology platform is built. The company maintains a current good manufacturing practice (cGMP) cell‐processing facility to support late‐stage trials.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Sustained; as a core, protected process, it forms a durable barrier to entry. NurOwn has received orphan drug designations in multiple jurisdictions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Protocol and Trial Metrics\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 3b ENDURANCE study expected to enroll approximately \u003cstrong\u003e200\u003c\/strong\u003e participants.\u003c\/li\u003e\n\u003cli\u003ePhase 3b Part A duration: \u003cstrong\u003e24-week\u003c\/strong\u003e, randomized, double-blind, placebo-controlled period.\u003c\/li\u003e\n\u003cli\u003eBiomarker data collected at \u003cstrong\u003eseven\u003c\/strong\u003e longitudinal time points.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eFinance: 13-Week Cash Flow View Incorporating Q3 2025 Burn Rate by Friday\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe draft 13-week cash flow view incorporating the Q3 2025 burn rate is pending completion by Friday. The Q3 2025 Net Loss, representing the operational burn, was approximately \u003cstrong\u003e$2.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSummary of Key Financial Data as of September 30, 2025\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount (USD)\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarterly Operational Burn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development Expense (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eComponent of Burn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral \u0026amp; Administrative Expense (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eComponent of Burn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Restricted Cash (Period End)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$0.23 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLiquidity Position\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets (Period End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.38 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet Item\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccounts Payable (Period End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.42 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent Liability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockholders' Deficit (Period End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$7.69 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet Item\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516122423445,"sku":"bcli-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/bcli-vrio-analysis.png?v=1740154826","url":"https:\/\/dcf-model.com\/products\/bcli-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}